Loading
A phase 3 trial of docetaxel in lung cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., not yet recruiting.
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy is a phase 3, randomised interventional study registered as NCT07831863 by Mabwell (Shanghai) Bioscience Co., Ltd., with a registry enrolment figure of 600 participants, started 2026-10 and due to reach its primary completion in 2029-03. Interventions recorded: 7MW3711; Docetaxel. Conditions listed: Lung Squamous Cell Carcinoma. Primary outcome: Overall Survival. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed unresectable locally advanced or metastatic squamous non-small cell lung cancer (NSCLC)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Squamous cell carcinoma of the lung, Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Docetaxel, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Squamous cell carcinoma of the lung, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.